CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade AstraZeneca PLC - GBP - AZNl CFD

    110.06
    0.33%
    0.28
    Low: 109.63
    High: 111.48
    Market Trading Hours* (UTC) Open now
    Closes on Thursday at 15:30

    Mon - Fri: 07:00 - 11:00 11:03 - 15:30

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.28
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.025255 %
    Charges from full value of position ($-4.80)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.025255%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003337 %
    Charges from full value of position ($0.63)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003337%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency GBP
    Margin 5%
    Stock exchange United Kingdom of Great Britain and Northern Ireland
    Commission on trade 0%

    *Information provided by Capital.com

    AstraZeneca PLC ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 110.42
    Open* 111.18
    1-Year Change* 12.16%
    Day's Range* 109.63 - 111.48
    52 wk Range 94.99-123.92
    Average Volume (10 days) 995.21K
    Average Volume (3 months) 36.82M
    Market Cap 168.19B
    P/E Ratio 34.26
    Shares Outstanding 1.55B
    Revenue 35.66B
    EPS 3.17
    Dividend (Yield %) 2.16741
    Beta 0.25
    Next Earnings Date Nov 9, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 27, 2023 110.42 -1.16 -1.04% 111.58 112.82 110.42
    Sep 26, 2023 111.50 0.12 0.11% 111.38 112.48 110.66
    Sep 25, 2023 111.26 0.12 0.11% 111.14 112.48 110.20
    Sep 22, 2023 110.42 1.89 1.74% 108.53 111.76 108.21
    Sep 21, 2023 108.49 -0.42 -0.39% 108.91 110.64 108.49
    Sep 20, 2023 108.13 0.86 0.80% 107.27 109.31 106.49
    Sep 19, 2023 105.77 0.22 0.21% 105.55 106.25 105.03
    Sep 18, 2023 106.37 -2.92 -2.67% 109.29 110.14 106.37
    Sep 15, 2023 108.43 0.20 0.18% 108.23 109.92 107.99
    Sep 14, 2023 107.41 1.94 1.84% 105.47 108.07 105.39
    Sep 13, 2023 105.27 -1.12 -1.05% 106.39 106.69 105.27
    Sep 12, 2023 106.83 1.60 1.52% 105.23 107.11 105.07
    Sep 11, 2023 103.99 -3.96 -3.67% 107.95 108.31 103.53
    Sep 8, 2023 107.33 -0.80 -0.74% 108.13 108.71 107.33
    Sep 7, 2023 108.05 2.20 2.08% 105.85 108.17 105.57
    Sep 6, 2023 105.99 0.30 0.28% 105.69 106.53 105.25
    Sep 5, 2023 106.45 0.44 0.42% 106.01 107.85 106.01
    Sep 4, 2023 106.77 0.08 0.07% 106.69 107.89 106.23
    Sep 1, 2023 106.87 0.92 0.87% 105.95 107.23 105.71
    Aug 31, 2023 106.83 -0.06 -0.06% 106.89 107.89 106.51

    AstraZeneca PLC - GBP Events

    Time (UTC) Country Event
    Friday, September 29, 2023

    Time (UTC)

    10:59

    Country

    GB

    Event

    AstraZeneca PLC at Citi European Healthcare Bus Trip
    AstraZeneca PLC at Citi European Healthcare Bus Trip

    Forecast

    -

    Previous

    -
    Monday, October 23, 2023

    Time (UTC)

    17:00

    Country

    GB

    Event

    AstraZeneca PLC Meet the Management European Society for Medical Oncology Congress
    AstraZeneca PLC Meet the Management European Society for Medical Oncology Congress

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 44351 37417 26617 24384 22090
    Revenue 44351 37417 26617 24384 22090
    Cost of Revenue, Total 8649 9542 5270 4824 4246
    Gross Profit 35702 27875 21347 19560 17844
    Total Operating Expense 40594 36361 21455 21460 18703
    Selling/General/Admin. Expenses, Total 13512 11519 9338 8964 8479
    Research & Development 9612 8519 6094 5320 5266
    Depreciation / Amortization 4094 3044 1897 1812 1945
    Unusual Expense (Income) 4820 3846 -763 863 -953
    Other Operating Expenses, Total -93 -109 -381 -323 -280
    Operating Income 3757 1056 5162 2924 3387
    Interest Income (Expense), Net Non-Operating -815 -819 -716 -766 -775
    Other, Net -441 -502 -530 -610 -619
    Net Income Before Taxes 2501 -265 3916 1548 1993
    Net Income After Taxes 3293 115 3144 1227 2050
    Minority Interest -5 -3 52 108 105
    Net Income Before Extra. Items 3288 112 3196 1335 2155
    Net Income 3288 112 3196 1335 2155
    Income Available to Common Excl. Extra. Items 3288 112 3196 1335 2155
    Income Available to Common Incl. Extra. Items 3288 112 3196 1335 2155
    Dilution Adjustment 0 0
    Diluted Net Income 3288 112 3196 1335 2155
    Diluted Weighted Average Shares 1560 1427 1313 1301 1267
    Diluted EPS Excluding Extraordinary Items 2.10769 0.07849 2.43412 1.02613 1.70087
    Dividends per Share - Common Stock Primary Issue 2.89361 2.84245 2.83031 2.89446 2.74532
    Diluted Normalized EPS 3.8859 2.22705 1.88804 1.48501 0.85399
    Interest Expense (Income) - Net Operating 0 0
    Total Extraordinary Items
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 11416 10879 11207 10982 10771
    Revenue 11416 10879 11207 10982 10771
    Cost of Revenue, Total 1974 2053 2417 2118 1904
    Gross Profit 9442 8826 8790 8864 8867
    Total Operating Expense 8960 8330 10113 9737 10232
    Selling/General/Admin. Expenses, Total 4102 3196 3469 3353 3633
    Research & Development 2570 2299 2638 2357 2431
    Depreciation / Amortization 952 954 1034 979 983
    Unusual Expense (Income) 109 108 331 1002 1298
    Other Operating Expenses, Total -747 -280 224 -72 -17
    Operating Income 2456 2549 1094 1245 539
    Interest Income (Expense), Net Non-Operating -368 -287 -316 -323 -292
    Net Income Before Taxes 2088 2262 778 922 247
    Net Income After Taxes 1820 1804 902 1642 360
    Minority Interest -2 -1 -1 -2 0
    Net Income Before Extra. Items 1818 1803 901 1640 360
    Net Income 1818 1803 901 1640 360
    Income Available to Common Excl. Extra. Items 1818 1803 901 1640 360
    Income Available to Common Incl. Extra. Items 1818 1803 901 1640 360
    Dilution Adjustment
    Diluted Net Income 1818 1803 901 1640 360
    Diluted Weighted Average Shares 1560 1560 1560 1559 1560
    Diluted EPS Excluding Extraordinary Items 1.16538 1.15577 0.57756 1.05196 0.23077
    Dividends per Share - Common Stock Primary Issue 0.91215 0 1.9694 0 0.93017
    Diluted Normalized EPS 1.22629 1.21098 0.70833 0.99743 0.80833
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 22593 26244 19544 15563 15591
    Cash and Short Term Investments 6405 6398 7992 6218 5680
    Cash 1411 1461 1182 755 893
    Cash & Equivalents 4755 4868 6650 4614 3938
    Short Term Investments 239 69 160 849 849
    Total Receivables, Net 9923 8795 5651 5181 4345
    Accounts Receivable - Trade, Net 7508 6324 3956 3813 2995
    Total Inventory 4699 8983 4024 3193 2890
    Prepaid Expenses 1329 1512 1735 865 1436
    Other Current Assets, Total 237 556 142 106 1240
    Total Assets 96483 105363 66729 61377 60651
    Property/Plant/Equipment, Total - Net 9449 10171 8917 8335 7421
    Property/Plant/Equipment, Total - Gross 17192 18495 17110 15852 14639
    Accumulated Depreciation, Total -7743 -8324 -8193 -7517 -7218
    Goodwill, Net 19820 19997 11845 11668 11707
    Intangibles, Net 39307 42387 20947 20833 21959
    Long Term Investments 1142 1237 1147 1459 922
    Note Receivable - Long Term 592 504 325 348 515
    Other Long Term Assets, Total 3580 4823 4004 3171 2536
    Total Current Liabilities 26293 22594 20307 18117 16292
    Accounts Payable 2550 2824 2350 1774 1720
    Accrued Expenses 8303 8079 4994 5085 5148
    Notes Payable/Short Term Debt 261 294 370 154 160
    Current Port. of LT Debt/Capital Leases 5281 1599 2016 1856 1594
    Other Current Liabilities, Total 9898 9798 10577 9248 7670
    Total Liabilities 59446 66095 51107 48250 48183
    Total Long Term Debt 23690 28888 17994 16217 17359
    Long Term Debt 22965 28134 17505 15730 17359
    Capital Lease Obligations 725 754 489 487 0
    Deferred Income Tax 2944 6206 2918 2490 3286
    Minority Interest 21 19 16 1469 1576
    Other Liabilities, Total 6498 8388 9872 9957 9670
    Total Equity 37037 39268 15622 13127 12468
    Common Stock 387 387 328 328 317
    Additional Paid-In Capital 35155 35126 7971 7941 4427
    Retained Earnings (Accumulated Deficit) 1495 3755 7323 4858 7724
    Total Liabilities & Shareholders’ Equity 96483 105363 66729 61377 60651
    Total Common Shares Outstanding 1549.8 1549.4 1312.67 1312.14 1267.04
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 22266 22593 20224 20917 22647
    Cash and Short Term Investments 6462 6405 4898 4887 5823
    Cash & Equivalents 6232 6166 4458 4817 5762
    Short Term Investments 230 239 440 70 61
    Total Receivables, Net 10797 11252 10061 9612 9050
    Accounts Receivable - Trade, Net 10289 10521 9336 8908 8683
    Total Inventory 4967 4699 5078 6220 7624
    Other Current Assets, Total 40 237 187 198 150
    Total Assets 96687 96483 94185 96579 100273
    Property/Plant/Equipment, Total - Net 9599 9449 9227 9627 10015
    Goodwill, Net 20001 19820 19707 19821 19963
    Intangibles, Net 39291 39307 39585 39900 41265
    Long Term Investments 1234 1142 1102 1180 1237
    Note Receivable - Long Term 682 835 792 881 864
    Other Long Term Assets, Total 3614 3337 3548 4253 4282
    Total Current Liabilities 24860 26293 24850 21815 22740
    Payable/Accrued 19210 19040 17694 17821 17864
    Notes Payable/Short Term Debt 568 261 584 636 724
    Current Port. of LT Debt/Capital Leases 3289 5281 5034 1746 1570
    Other Current Liabilities, Total 1793 1711 1538 1612 2582
    Total Liabilities 60898 59446 59051 60647 63933
    Total Long Term Debt 27646 23690 23681 27146 28805
    Long Term Debt 26916 22965 23013 26461 28081
    Capital Lease Obligations 730 725 668 685 724
    Deferred Income Tax 2795 2944 3479 5275 5626
    Minority Interest 22 21 20 19 19
    Other Liabilities, Total 5575 6498 7021 6392 6743
    Total Equity 35789 37037 35134 35932 36340
    Common Stock 387 387 387 387 387
    Additional Paid-In Capital 35159 35155 35137 35134 35131
    Retained Earnings (Accumulated Deficit) 243 1495 -390 411 822
    Total Liabilities & Shareholders’ Equity 96687 96483 94185 96579 100273
    Total Common Shares Outstanding 1549.85 1549.8 1549.51 1549.48 1549.45
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 2501 -265 3916 1548 1993
    Cash From Operating Activities 9808 5963 4799 2969 2618
    Cash From Operating Activities 5480 6530 3149 3762 3753
    Non-Cash Items 542 141 -332 -103 -1276
    Cash Taxes Paid 1623 1743 1562 1118 537
    Cash Interest Paid 849 721 733 774 676
    Changes in Working Capital 1285 -443 -1934 -2238 -1852
    Cash From Investing Activities -2960 -11058 -285 -657 963
    Capital Expenditures -2571 -2200 -2606 -2460 -1371
    Other Investing Cash Flow Items, Total -389 -8858 2321 1803 2334
    Cash From Financing Activities -6823 3649 -2203 -1765 -2044
    Financing Cash Flow Items -1047 -178 -101 4 -67
    Total Cash Dividends Paid -4364 -3856 -3572 -3592 -3484
    Issuance (Retirement) of Stock, Net 29 29 30 3525 34
    Issuance (Retirement) of Debt, Net -1441 7654 1440 -1702 1473
    Foreign Exchange Effects -80 -62 12 5 -38
    Net Change in Cash -55 -1508 2323 552 1499
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line 2262 2501 1723 800 553
    Cash From Operating Activities 3133 9808 7410 4480 3232
    Cash From Operating Activities 1502 5480 4000 2666 1309
    Non-Cash Items -391 542 172 15 -12
    Cash Taxes Paid 225 1623 1335 1006 228
    Cash Interest Paid 257 849 608 386 194
    Changes in Working Capital -240 1285 1515 999 1382
    Cash From Investing Activities -1246 -2960 -2711 -968 -168
    Capital Expenditures -1470 -2571 -2017 -906 -363
    Other Investing Cash Flow Items, Total 224 -389 -694 -62 195
    Cash From Financing Activities -2031 -6823 -6465 -5035 -3740
    Financing Cash Flow Items -840 -1047 -1047 -997 -997
    Total Cash Dividends Paid -3047 -4364 -4364 -2971 -2971
    Issuance (Retirement) of Stock, Net 4 29 11 8 5
    Issuance (Retirement) of Debt, Net 1852 -1441 -1065 -1075 223
    Foreign Exchange Effects -11 -80 -86 -35 -9
    Net Change in Cash -155 -55 -1852 -1558 -685
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    BlackRock Institutional Trust Company, N.A. Investment Advisor 6.5097 100893184 1200 2023-01-31 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 4.1998 65092368 768 2023-01-31 LOW
    Investor AB Private Equity 3.3299 51608948 608 2023-01-31 LOW
    Capital Research Global Investors Investment Advisor 2.9885 46318144 1187159 2023-03-01 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.8215 43729918 -216226 2023-03-01 LOW
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 2.2154 34336191 -195287 2023-08-01 LOW
    Capital World Investors Investment Advisor 1.8533 28724760 1470886 2023-03-01 LOW
    BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 1.3109 20317095 0 2023-08-01 LOW
    BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 1.1923 18479536 71333 2023-08-01 LOW
    GQG Partners, LLC Investment Advisor 1.0668 16534104 -45058 2023-03-01 MED
    Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.9221 14291718 -714464 2023-08-01 LOW
    State Street Global Advisors (UK) Ltd. Investment Advisor/Hedge Fund 0.7444 11537597 8907 2023-08-01 LOW
    Aviva Investors Global Services Limited Investment Advisor/Hedge Fund 0.5501 8526391 55270 2023-08-01 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5489 8507378 121134 2023-03-01 LOW
    Nuveen LLC Pension Fund 0.5441 8432544 -1110811 2023-02-07 LOW
    Handelsbanken Kapitalförvaltning AB Investment Advisor/Hedge Fund 0.5193 8048865 62522 2023-07-31 LOW
    Fidelity Management & Research Company LLC Investment Advisor 0.5141 7967485 7544 2023-08-01 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.4862 7535152 -16872 2023-08-01 LOW
    M & G Investment Management Ltd. Investment Advisor 0.4825 7477805 87130 2023-08-01 LOW
    Union Investment Privatfonds GmbH Investment Advisor 0.4153 6437102 654523 2023-03-31 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    AstraZeneca - GBP Company profile

    About AstraZeneca plc

    AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.

    Industry: Pharmaceuticals (NEC)

    1 Francis Crick Avenue
    CAMBRIDGE
    CAMBRIDGESHIRE CB2 0AA
    GB

    Income Statement

    • Annual
    • Quarterly

    News

    How to Trade The Triple Top

    Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

    14:13, 27 September 2023
    USA flag on the background of stock charts. Financial system in USA

    Q4 lookahead: US indices starting to show signs of trouble?

    US indices start to draw attention as traders focus on the outlook for Q4.

    07:20, 27 September 2023

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    People also watch

    XRP/USD

    0.51 Price
    -0.310% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    BTC/USD

    26,509.45 Price
    +0.880% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    Oil - Crude

    92.53 Price
    -0.620% 1D Chg, %
    Long position overnight fee 0.0587%
    Short position overnight fee -0.0806%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    ETH/USD

    1,625.76 Price
    +1.840% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading